Shopping Cart 0
Cart Subtotal
USD 0

OncoMed Pharmaceuticals Inc (OMED) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 750
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Summary

OncoMed Pharmaceuticals Inc (OncoMed) is a clinical-stage biopharmaceutical company focused on discovery and development of novel immuno-oncology (IO) therapeutics for the treatment of cancers. Its pipeline product candidates include navicixizumab, rosmantuzumab, Gitrl-FC Trimer, and anti-TIGIT. OncoMed's research platform enables to build a portfolio of active therapeutic compounds that target biologic pathways critical for the growth, resistance, recurrence, and metastasis of cancer. The company's expertise spans across cancer research, drug discovery, clinical development, regulatory affairs, translational medicine and commercial development. The company has strategic alliances with Celgene Corporation, Bayer Pharma AG and GlaxoSmithKline for the advancement of its clinical-stage candidates. OncoMed is headquartered in Redwood, California, the US.

OncoMed Pharmaceuticals Inc (OMED)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

OncoMed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

OncoMed Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

OncoMed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

OncoMed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

OncoMed Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10

OncoMed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

OncoMed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 12

Partnerships 12

OncoMed Pharma Partners with Guardant Health 12

OncoMed Pharma Enters Into Co-Development Agreement With Celgene 13

Genomic Health Enters Into Co-Development Agreement With OncoMed Pharma 15

Molecular Response Enters Into Co-Development Agreement With OncoMed Pharma 16

Licensing Agreements 17

Lonza Enters Into Licensing Agreement With OncoMed Pharma For GS Gene Expression System 17

Equity Offering 18

OncoMed Pharma Plans to Raise USD150 Million in Public Offering of Securities 18

OncoMed Pharma Raises USD4.9 Million in Public offering of Shares 19

OncoMed Pharma Raises USD63.3 Million in Public Offering of Shares 20

OncoMed Pharma Completes IPO Of Shares For USD 93.8 Million 22

OncoMed Pharmaceuticals Inc-Key Competitors 24

OncoMed Pharmaceuticals Inc-Key Employees 25

OncoMed Pharmaceuticals Inc-Locations And Subsidiaries 26

Head Office 26

Recent Developments 27

Financial Announcements 27

Aug 02, 2018: OncoMed announces second quarter 2018 financial results and operational highlights 27

May 08, 2018: OncoMed Announces First Quarter 2018 Financial Results and Operational Highlights 29

Mar 08, 2018: OncoMed Announces Fourth Quarter and Full Year 2017 Financial Results and Operational Highlights 31

Nov 02, 2017: OncoMed Announces Third Quarter 2017 Financial Results and Operational Highlights 33

Aug 02, 2017: OncoMed Announces Second Quarter 2017 Financial Results 35

May 08, 2017: OncoMed Announces First Quarter 2017 Financial Results and Demcizumab DENALI Results 36

Corporate Communications 38

Mar 19, 2018: OncoMed Names John Lewicki As President, CEO And Board Member 38

Jan 04, 2018: OncoMed Announces Chairman, President and Chief Executive Officer Paul J. Hastings has Resigned 39

Nov 27, 2017: OncoMed Announces Chairman, President and Chief Executive Officer Paul J. Hastings to Resume Chairman Responsibilities 40

Apr 24, 2017: OncoMed Announces Workforce Reduction 41

Clinical Trials 42

Jun 12, 2018: OncoMed Doses First Patient in Phase 1b Portion of anti-TIGIT Clinical Trial 42

Apr 18, 2018: OncoMed Presents Preclinical Abstract On anti-TIGIT (OMP-313M32) At The 2018 American Association for Cancer Research Annual Meeting 43

Apr 09, 2018: OncoMed to Present Preclinical Data for OMP-313M32 at the 2018 American Association for Cancer Research Annual Meeting 44

Sep 13, 2017: OncoMed Doses First Patient with GITRL-Fc in Phase 1a Clinical Trial 45

May 04, 2017: OncoMed Doses First Patient with Anti-TIGIT Antibody in Phase 1 Clinical Trial 46

Apr 05, 2017: OncoMed Announces Presentation on Rosmantuzumab at the American Association for Cancer Research Annual Meeting 2017 47

Apr 05, 2017: OncoMed Highlights Data Presented on GITRL-Fc trimer at the American Association for Cancer Research Annual Meeting 2017 48

Apr 03, 2017: OncoMed Presents Preclinical Data for Anti-TIGIT Program at the American Association for Cancer Research Annual Meeting 2017 49

Feb 13, 2017: OncoMed Enrolls First Patient in Phase 1b Clinical Trial of its Anti-DLL4/VEGF Bispecific Antibody in Patients with Platinum-Resistant Ovarian Cancer 51

Jan 04, 2017: OncoMed Initiates Enrollment of Phase 1b Clinical Trial of Anti-DLL4/VEGF Bispecific Antibody as Second-line Treatment for Metastatic Colorectal Cancer Patients 52

Other Significant Developments 53

Jan 04, 2018: OncoMed Provides 2018 Outlook and 2017 Year-End Cash Balance and Announces an Update on the Rosmantuzumab Program 53

Jan 05, 2017: OncoMed Announces Year-End Cash Balance and 2017 Outlook 54

Appendix 56

Methodology 56

About GlobalData 56

Contact Us 56

Disclaimer 56


List Of Figure

List of Figures

OncoMed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

OncoMed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

OncoMed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

OncoMed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

OncoMed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

OncoMed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

OncoMed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

OncoMed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

OncoMed Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10


List Of Table

List of Tables

OncoMed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

OncoMed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

OncoMed Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

OncoMed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

OncoMed Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9

OncoMed Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10

OncoMed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

OncoMed Pharma Partners with Guardant Health 12

OncoMed Pharma Enters Into Co-Development Agreement With Celgene 13

Genomic Health Enters Into Co-Development Agreement With OncoMed Pharma 15

Molecular Response Enters Into Co-Development Agreement With OncoMed Pharma 16

Lonza Enters Into Licensing Agreement With OncoMed Pharma For GS Gene Expression System 17

OncoMed Pharma Plans to Raise USD150 Million in Public Offering of Securities 18

OncoMed Pharma Raises USD4.9 Million in Public offering of Shares 19

OncoMed Pharma Raises USD63.3 Million in Public Offering of Shares 20

OncoMed Pharma Completes IPO Of Shares For USD 93.8 Million 22

OncoMed Pharmaceuticals Inc, Key Competitors 24

OncoMed Pharmaceuticals Inc, Key Employees 25

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

OncoMed Pharmaceuticals Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.